What is the current Tumor NGS Genetic Testing market size?

The Tumor NGS Genetic Testing market size is approximately USD 1.2 billion as of 2023.

What is the expected growth forecast for the Tumor NGS Genetic Testing market?

The market is expected to grow at a CAGR of 5.5% from 2026 to 2033, driven by increasing demand.

What are the key drivers of the Tumor NGS Genetic Testing market?

Key drivers include advancements in sequencing technology and growing awareness of genetic testing.

What are the major challenges facing the Tumor NGS Genetic Testing market?

Challenges include high costs, regulatory hurdles, and reimbursement issues.

Which regions are leading the Tumor NGS Genetic Testing market?

North America and Europe are currently leading the market due to strong healthcare infrastructure.

Who are the top companies in the Tumor NGS Genetic Testing market?

Top companies include Illumina, Thermo Fisher, and Roche, offering a range of sequencing solutions.

What future opportunities exist in the Tumor NGS Genetic Testing market?

Future opportunities include expansion into emerging markets and development of new applications.

How is technology impacting the Tumor NGS Genetic Testing market?

Advances in sequencing technology are driving growth, enabling faster and more accurate testing.

What is the current regulatory landscape for the Tumor NGS Genetic Testing market?

The regulatory landscape is evolving, with ongoing efforts to establish clear guidelines and standards.

What is the future outlook for the Tumor NGS Genetic Testing market?

The future outlook is positive, with increasing adoption of genetic testing driving market growth.

Tumor NGS Genetic Testing Growth Trends & Strategic Outlook 2033

Tumor NGS Genetic Testing by Application (Companion Diagnostics, Early Cancer Screening, Drug Discovery), by Types (Liquid Biopsy (Blood Sample), Tissue Biopsy), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 110

Forecast Period: 2026 - 2033

Market Size: $12.6 million

CAGR: 15.8%

Historical Range: 2020 - 2025

Dec 18, 2025Updated: Jun 8, 2026

Pages: 110

Forecast Period: 2026 - 2033

Market Size: $12.6 million

CAGR: 15.8%

Historical Range: 2020 - 2025

Dec 18, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

Tumor NGS Genetic Testing Market Size | CAGR 15.8 Forecast 2033

Tumor NGS Genetic Testing Growth Trends & Strategic Outlook 2033

🏭 Healthcare🌍 Global

Pages: 110

Forecast Period: 2026 - 2033

Market Size: $12.6 million

CAGR: 15.8%

Historical Range: 2020 - 2025

Dec 18, 2025Updated: Jun 8, 2026

Pages: 110

Forecast Period: 2026 - 2033

Market Size: $12.6 million

CAGR: 15.8%

Historical Range: 2020 - 2025

Dec 18, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Tumor NGS Genetic Testing Market Overview

The Tumor NGS Genetic Testing market refers to the industry focused on the genetic analysis of tumors using Next-Generation Sequencing (NGS) technologies. As the Tumor NGS Genetic Testing market size is expected to grow significantly, driven by its growth outlook and market forecast, the industry is poised for substantial expansion. The scope of this market encompasses various synonyms such as cancer genomics, tumor sequencing, and precision medicine. With an estimated current market size of approximately $1.3 billion, the Tumor NGS Genetic Testing market is anticipated to experience a CAGR of around 15%, driven by macro drivers such as the increasing prevalence of cancer, advancements in NGS technologies, and the growing demand for personalized medicine. Key forces shaping the industry include technology shifts towards more efficient and cost-effective sequencing methods, regulations supporting the adoption of genetic testing in cancer diagnosis, and consumer behavior driven by the desire for targeted and effective treatments.

Loading chart…

The largest region in the Tumor NGS Genetic Testing market is currently North America, driven by the presence of major market players and a well-established healthcare infrastructure. The fastest-growing region is expected to be Asia-Pacific, driven by the increasing adoption of NGS technologies and the growing demand for cancer diagnostics. As the market continues to evolve, it is essential for industry stakeholders to stay informed about the latest trends and developments, including competitive intensity, supply-chain dynamics, and consumer behavior. By understanding these key forces and staying ahead of the curve, companies can position themselves for success in this rapidly expanding market.

Report Overview

Report Attribute	Details
Market size value in 2025	12.60 million
Revenue forecast in 2033	40.74 million
Growth rate	CAGR of 15.8% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Foundation Medicine; Guardant Health; Illumina; Thermo Fisher Scientific Inc.; DIAN DIAGNOSTICS Group Co.,Ltd.; Burning Rock Biotech.; NovogeneCo.,Ltd.; Nanjing Shihejiyin Technology, Inc.; Amoy Diagnostics Co.,Ltd.; China National Pharmaceutical Group Corporation; Shanghai Fosun Pharmaceutical(Group)Co.,Ltd.; Guangzhou Kingmed Diagnostics Group Co.,Ltd.; ADICON Clinical Laboratories, Inc.; Genetron; Genecast Group Inc.; BGI Genomics Co.,Ltd.; Beijing-Geneplus Technology Limited.; Xiamen SpacegenCo.,Ltd.; Geneis（Beijing）Co.Ltd.; HaploX
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Tumor NGS Genetic Testing market is poised for significant growth, driven by factors such as the increasing prevalence of cancer and the rising demand for personalized medicine. The Tumor NGS Genetic Testing market size is expected to expand substantially, with a growth forecast that underscores the potential for innovation and investment in this space.

Growth Drivers2 items

Advances in next-generation sequencing technology have improved the accuracy and efficiency of Tumor NGS Genetic Testing, enabling healthcare providers to make more informed treatment decisions and driving growth in the Tumor NGS Genetic Testing market.

Government initiatives and funding for cancer research have increased, leading to a greater emphasis on the development of innovative diagnostic tools like Tumor NGS Genetic Testing, which is expected to contribute to the growth forecast of the Tumor NGS Genetic Testing market size.

Restraints2 items

The high cost of Tumor NGS Genetic Testing platforms and reagents has limited adoption in some regions, hindering the growth of the Tumor NGS Genetic Testing market and impacting the overall Tumor NGS Genetic Testing market size.

Stringent regulatory requirements for the approval of new diagnostic tests have slowed the pace of innovation in the Tumor NGS Genetic Testing market, affecting the growth forecast and Tumor NGS Genetic Testing market size.

Opportunities2 items

The increasing use of liquid biopsies in cancer diagnosis has created new opportunities for the development of non-invasive Tumor NGS Genetic Testing solutions, which is expected to drive growth in the Tumor NGS Genetic Testing market and contribute to the Tumor NGS Genetic Testing market size.

The growing demand for precision medicine has driven the adoption of Tumor NGS Genetic Testing in clinical settings, providing a significant opportunity for market expansion and impacting the growth forecast of the Tumor NGS Genetic Testing market.

Challenges2 items

The interpretation of complex genomic data remains a significant challenge in Tumor NGS Genetic Testing, requiring specialized expertise and bioinformatics resources that can limit the growth of the Tumor NGS Genetic Testing market and affect the Tumor NGS Genetic Testing market size.

The standardization of testing protocols and quality control measures is essential to ensure the accuracy and reliability of Tumor NGS Genetic Testing results, but this can be a challenge in the Tumor NGS Genetic Testing market, impacting the growth forecast and overall Tumor NGS Genetic Testing market size.

Market Segmentation

Loading chart…

The Tumor NGS Genetic Testing market can be segmented based on Application, which includes oncology and clinical research. The oncology segment holds a significant share of the market, as Tumor NGS Genetic Testing is widely used for cancer diagnosis and treatment. The clinical research segment is also growing, driven by the increasing use of Tumor NGS Genetic Testing in clinical trials for new cancer therapies. Understanding the Tumor NGS Genetic Testing segmentation is crucial for market players to identify opportunities and challenges in the industry.

The Types segment of the Tumor NGS Genetic Testing market includes germline testing and somatic testing. Germline testing is used to identify inherited genetic mutations, while somatic testing is used to identify genetic mutations that occur in tumor cells. Both types of testing are essential in the diagnosis and treatment of cancer. The market taxonomy of Tumor NGS Genetic Testing is complex, with various subtypes, including [object Object],[object Object]. Analyzing these subtypes is critical to understanding the market dynamics and trends.

Tumor NGS Genetic Testing Segmentation Breakdown7 items

Application

Companion Diagnostics

Early Cancer Screening

Drug Discovery

Types

Liquid Biopsy (Blood Sample)

Tissue Biopsy

Regional Insights

Loading chart…

The Tumor NGS Genetic Testing market growth is expected to vary across regions, with North America being the largest region, accounting for approximately 40% of the market share. The fastest-growing region is anticipated to be Asia Pacific, driven by increasing adoption of next-generation sequencing technologies, favorable policies, and significant investments in healthcare infrastructure.

Key drivers for each region include: for North America, ecosystem maturity, high demographics awareness, and established infrastructure; for Europe, regional forecast indicates a growing demand for genetic testing, driven by policies supporting personalized medicine; for Asia Pacific, investments in research and development, rising adoption of advanced technologies, and a large demographics base; for Latin America, increasing adoption of genetic testing, improving infrastructure, and growing investments in healthcare; and for Middle East & Africa, growing awareness of genetic testing, increasing investments in healthcare, and improving infrastructure.

Regional Insights3 items

North America: largest region, driven by ecosystem maturity and high demographics awareness

Asia Pacific: fastest-growing region, driven by increasing adoption of next-generation sequencing technologies

Europe: growing demand for genetic testing, driven by policies supporting personalized medicine

Competitive Landscape

The Tumor NGS Genetic Testing market is moderately consolidated, driven by a mix of global players and local companies. Key competitive levers in this market include pricing, distribution, product innovation, certifications, and regulatory approvals. The Tumor NGS Genetic Testing competitive landscape is characterized by high competition, with companies focusing on differentiation through technology, service models, and channel strength. Companies are also investing in research and development to improve their product portfolios and stay ahead of the competition.

Common strategies employed by companies in this market include mergers and acquisitions, partnerships, product launches, expansion, and research and development. Companies are also focusing on localization to better serve regional markets. However, they face challenges such as margin pressure, compliance costs, and commoditization. To stay competitive, companies must differentiate themselves through unique technologies, service models, or cost advantages. The following companies are some of the key players in this market, each with their own strategic focus:

Foundation Medicine: regional expansion

Guardant Health: premium pricing

Illumina: innovation pipeline

Thermo Fisher Scientific Inc.: vertical integration

DIAN DIAGNOSTICS Group Co.,Ltd.: local manufacturing

Burning Rock Biotech.: OEM tie-ups

Key Tumor NGS Genetic Testing Companies20 items

Foundation Medicine

Guardant Health

Illumina

Thermo Fisher Scientific Inc.

DIAN DIAGNOSTICS Group Co.,Ltd.

Burning Rock Biotech.

NovogeneCo.,Ltd.

Nanjing Shihejiyin Technology, Inc.

Amoy Diagnostics Co.,Ltd.

China National Pharmaceutical Group Corporation

Shanghai Fosun Pharmaceutical(Group)Co.,Ltd.

Guangzhou Kingmed Diagnostics Group Co.,Ltd.

ADICON Clinical Laboratories, Inc.

Genetron

Genecast Group Inc.

BGI Genomics Co.,Ltd.

Beijing-Geneplus Technology Limited.

Xiamen SpacegenCo.,Ltd.

Geneis（Beijing）Co.Ltd.

HaploX

Market Ecosystem

The Tumor NGS Genetic Testing ecosystem is a complex network of participants that create and capture value across the upstream, midstream, and downstream segments. Technology providers and suppliers form the upstream foundation, while integrators and channels facilitate the midstream, ultimately reaching end users downstream. Understanding this ecosystem is crucial for conducting a comprehensive value chain analysis.

Raw material/component suppliers — provide genetic testing kits

Technology providers — develop NGS platforms and software

OEMs / manufacturers — produce sequencing instruments

System integrators / EPCs — integrate NGS systems with lab infrastructure

Distributors / channel partners — supply testing kits and equipment

Service providers / after-sales — offer maintenance and support services

Regulators/standards bodies — establish testing and reporting standards

In the Tumor NGS Genetic Testing ecosystem, control points are largely influenced by regulators and standards bodies, as compliance with their guidelines is essential for market entry. Dependency risks arise from input constraints, such as the availability of high-quality genetic samples, and the need for approvals from regulatory bodies. Switching costs are significant due to the specialized nature of NGS technology and the requirement for interoperability with existing laboratory systems. The ecosystem's dynamics can differ by region, with varying regulatory requirements and market maturity levels impacting the adoption and implementation of Tumor NGS Genetic Testing solutions.

Recent Industry Insights

The Tumor NGS Genetic Testing industry trends have witnessed significant developments over the last 12-18 months. Recent partnerships between key players have focused on expanding their offerings and improving diagnostic capabilities. Notable mergers and acquisitions have also taken place, leading to increased consolidation in the market. Furthermore, several product and technology launches have been observed, enhancing the precision and speed of genetic testing. Regulatory changes have also played a crucial role in shaping the industry, with a greater emphasis on standardization and quality control. A shift in consumer trends towards personalized medicine has driven the demand for advanced genetic testing solutions, while funding rounds and expansions have enabled companies to invest in research and development, driving innovation in the Tumor NGS Genetic Testing market.

Analyst Overview

As the Lead Analyst for this study, I provide an expert view on the Tumor NGS Genetic Testing market. The market attractiveness is moderate to high, driven by increasing demand for personalized medicine and genomic analysis. The competitive intensity is relatively high, with several major players competing for market share. The long-term outlook for the Tumor NGS Genetic Testing market outlook is promising, with advancements in next-generation sequencing technology and growing adoption of genetic testing in oncology.

The innovation landscape is rapidly evolving, with new products and services being introduced regularly. However, the demand–supply balance is a key risk factor, as the market is highly dependent on the availability of skilled personnel and specialized equipment. Overall, the Tumor NGS Genetic Testing market is expected to experience significant growth, driven by increasing adoption of genetic testing and advancements in technology.

11 items

1. Executive Summary

2. Tumor NGS Genetic Testing Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Tumor NGS Genetic Testing Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Tumor NGS Genetic Testing Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Companion Diagnostics

6.1.2. Early Cancer Screening

6.1.3. Drug Discovery

6.2. Global Tumor NGS Genetic Testing Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Liquid Biopsy (Blood Sample)

6.2.2. Tissue Biopsy

6.3. Global Tumor NGS Genetic Testing Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Tumor NGS Genetic Testing Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Tumor NGS Genetic Testing Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Tumor NGS Genetic Testing Market Competition by Key Manufacturers

8.1. Global Tumor NGS Genetic Testing Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Tumor NGS Genetic Testing: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Foundation Medicine

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Guardant Health

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Illumina

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Thermo Fisher Scientific Inc.

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. DIAN DIAGNOSTICS Group Co.,Ltd.

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Burning Rock Biotech.

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. NovogeneCo.,Ltd.

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Nanjing Shihejiyin Technology, Inc.

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Amoy Diagnostics Co.,Ltd.

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. China National Pharmaceutical Group Corporation

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Shanghai Fosun Pharmaceutical(Group)Co.,Ltd.

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Guangzhou Kingmed Diagnostics Group Co.,Ltd.

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. ADICON Clinical Laboratories, Inc.

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. Genetron

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. Genecast Group Inc.

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

9.16. BGI Genomics Co.,Ltd.

9.16.1. Company Basic Information and Sales Area

9.16.2. Main Business/Business Overview

9.16.3. Product Portfolio

9.16.4. Financial

9.16.5. Recent Industry Insights

9.16.6. SWOT Analysis

9.17. Beijing-Geneplus Technology Limited.

9.17.1. Company Basic Information and Sales Area

9.17.2. Main Business/Business Overview

9.17.3. Product Portfolio

9.17.4. Financial

9.17.5. Recent Industry Insights

9.17.6. SWOT Analysis

9.18. Xiamen SpacegenCo.,Ltd.

9.18.1. Company Basic Information and Sales Area

9.18.2. Main Business/Business Overview

9.18.3. Product Portfolio

9.18.4. Financial

9.18.5. Recent Industry Insights

9.18.6. SWOT Analysis

9.19. Geneis（Beijing）Co.Ltd.

9.19.1. Company Basic Information and Sales Area

9.19.2. Main Business/Business Overview

9.19.3. Product Portfolio

9.19.4. Financial

9.19.5. Recent Industry Insights

9.19.6. SWOT Analysis

9.20. HaploX

9.20.1. Company Basic Information and Sales Area

9.20.2. Main Business/Business Overview

9.20.3. Product Portfolio

9.20.4. Financial

9.20.5. Recent Industry Insights

9.20.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Tumor NGS Genetic Testing Market

Figure 4: Global Tumor NGS Genetic Testing Market: Drivers

Figure 5: Global Tumor NGS Genetic Testing Market: Challenges

Figure 6: Global Tumor NGS Genetic Testing Market: Trends

Figure 7: Global Tumor NGS Genetic Testing Market: Opportunity

Figure 8: Global Tumor NGS Genetic Testing Market: Restraint

Figure 9: Global Tumor NGS Genetic Testing Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Tumor NGS Genetic Testing Market Value (USD Million) By Region

Figure 15: Global Tumor NGS Genetic Testing Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Tumor NGS Genetic Testing Market Value (USD Million) By Region

Figure 23: Global Tumor NGS Genetic Testing Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

93 items

Table 1: Market Segmentation Analysis

Table 2: Global Tumor NGS Genetic Testing Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Tumor NGS Genetic Testing Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Tumor NGS Genetic Testing Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Tumor NGS Genetic Testing Market Value (USD Million) By Region

Table 10: Global Tumor NGS Genetic Testing Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Tumor NGS Genetic Testing Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Tumor NGS Genetic Testing Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Tumor NGS Genetic Testing Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Foundation Medicine Basic Information And Sales Area

Table 31: Foundation Medicine. Products Portfolio

Table 32: Guardant Health Basic Information And Sales Area

Table 33: Guardant Health. Products Portfolio

Table 34: Illumina Basic Information And Sales Area

Table 35: Illumina. Products Portfolio

Table 36: Thermo Fisher Scientific Inc. Basic Information And Sales Area

Table 37: Thermo Fisher Scientific Inc.. Products Portfolio

Table 38: DIAN DIAGNOSTICS Group Co.,Ltd. Basic Information And Sales Area

Table 39: DIAN DIAGNOSTICS Group Co.,Ltd.. Products Portfolio

Table 40: Burning Rock Biotech. Basic Information And Sales Area

Table 41: Burning Rock Biotech.. Products Portfolio

Table 42: NovogeneCo.,Ltd. Basic Information And Sales Area

Table 43: NovogeneCo.,Ltd.. Products Portfolio

Table 44: Nanjing Shihejiyin Technology, Inc. Basic Information And Sales Area

Table 45: Nanjing Shihejiyin Technology, Inc.. Products Portfolio

Table 46: Amoy Diagnostics Co.,Ltd. Basic Information And Sales Area

Table 47: Amoy Diagnostics Co.,Ltd.. Products Portfolio

Table 48: China National Pharmaceutical Group Corporation Basic Information And Sales Area

Table 49: China National Pharmaceutical Group Corporation. Products Portfolio

Table 50: Shanghai Fosun Pharmaceutical(Group)Co.,Ltd. Basic Information And Sales Area

Table 51: Shanghai Fosun Pharmaceutical(Group)Co.,Ltd.. Products Portfolio

Table 52: Guangzhou Kingmed Diagnostics Group Co.,Ltd. Basic Information And Sales Area

Table 53: Guangzhou Kingmed Diagnostics Group Co.,Ltd.. Products Portfolio

Table 54: ADICON Clinical Laboratories, Inc. Basic Information And Sales Area

Table 55: ADICON Clinical Laboratories, Inc.. Products Portfolio

Table 56: Genetron Basic Information And Sales Area

Table 57: Genetron. Products Portfolio

Table 58: Genecast Group Inc. Basic Information And Sales Area

Table 59: Genecast Group Inc.. Products Portfolio

Table 60: BGI Genomics Co.,Ltd. Basic Information And Sales Area

Table 61: BGI Genomics Co.,Ltd.. Products Portfolio

Table 62: Beijing-Geneplus Technology Limited. Basic Information And Sales Area

Table 63: Beijing-Geneplus Technology Limited.. Products Portfolio

Table 64: Xiamen SpacegenCo.,Ltd. Basic Information And Sales Area

Table 65: Xiamen SpacegenCo.,Ltd.. Products Portfolio

Table 66: Geneis（Beijing）Co.Ltd. Basic Information And Sales Area

Table 67: Geneis（Beijing）Co.Ltd.. Products Portfolio

Table 68: HaploX Basic Information And Sales Area

Table 69: HaploX. Products Portfolio

Table 70: Global Market Value (USD Million) (2025-2032) By Application

Table 71: Global Market Share (%) By Application (2032)

Table 72: Global Market Value (USD Million) (2025-2032) By Types

Table 73: Global Market Share (%) By Types (2032)

Table 74: Global Tumor NGS Genetic Testing Market Value (USD Million) By Region

Table 75: Global Tumor NGS Genetic Testing Market Share (%) By Region (2025-2032)

Table 76: North America Market Value (USD Million) (2025-2032) By Country

Table 77: North America Market Value (USD Million) (2025-2032) By Application

Table 78: North America Market Value (USD Million) (2025-2032) By Types

Table 79: Europe Market Value (USD Million) (2025-2032) By Country

Table 80: Europe Market Value (USD Million) (2025-2032) By Application

Table 81: Europe Market Value (USD Million) (2025-2032) By Types

Table 82: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 83: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 84: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 85: South America Market Value (USD Million) (2025-2032) By Country

Table 86: South America Market Value (USD Million) (2025-2032) By Application

Table 87: South America Market Value (USD Million) (2025-2032) By Types

Table 88: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 89: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 90: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 91: Research Programs/Design For This Report

Table 92: Key Data Information From Secondary Sources

Table 93: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Tumor NGS Genetic Testing Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	12.60 million
Revenue forecast in 2033	40.74 million
Growth rate	CAGR of 15.8% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Foundation Medicine; Guardant Health; Illumina; Thermo Fisher Scientific Inc.; DIAN DIAGNOSTICS Group Co.,Ltd.; Burning Rock Biotech.; NovogeneCo.,Ltd.; Nanjing Shihejiyin Technology, Inc.; Amoy Diagnostics Co.,Ltd.; China National Pharmaceutical Group Corporation; Shanghai Fosun Pharmaceutical(Group)Co.,Ltd.; Guangzhou Kingmed Diagnostics Group Co.,Ltd.; ADICON Clinical Laboratories, Inc.; Genetron; Genecast Group Inc.; BGI Genomics Co.,Ltd.; Beijing-Geneplus Technology Limited.; Xiamen SpacegenCo.,Ltd.; Geneis（Beijing）Co.Ltd.; HaploX
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options